Erratum (DOI:10.1016/j.bbmt.2008.10.023);Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1, 2009, Pages 54-60

  Behrendt, Carolyn E ^a   Rosenthal, Joseph ^a   Bolotin, Ellen ^a   Nakamura, Ryotaro ^a   Zaia, John ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Acute leukemia; Cytomegalovirus; Hematopoietic stem cell transplantation; Pediatric; Prognosis

Indexed keywords

ACICLOVIR; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INCIDENCE; INFANT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; ORGAN DONOR; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SEROPREVALENCE; SIBLING; TREATMENT FAILURE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VIRUS ISOLATION; WHOLE BODY RADIATION;

EID: 58149204030     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.03.005     Document Type: Erratum

References (30)

1. Boeckh M., and Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103 (2004) 2003-2008
2. Nichols W.G., Corey L., Gooley T., Davis C., and Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185 (2002) 273-282
3. Boeckh M., and Nichols W.G. Immunosuppressive effects of beta-herpes viruses. Herpes 10 (2003) 12-16
4. Broers A.E., van Der Holt R., van Esser J.W., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell depleted stem cell transplantation. Blood 95 (2000) 2240-2245
5. Cornelissen J.J., Carston M., Kollman C., et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97 (2001) 1572-1577
6. Ljungman P., Reusser P., de la Camara R., et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 33 (2004) 1075-1081
7. Ljungman P. Risk assessment in haematopoietic stem cell transplantation: viral status. Best Pract Res Clin Haematol 20 (2007) 209-217
8. Nachbaur D., Clausen J., and Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol 76 (2006) 414-419
9. Jacobsen N., Badsberg J.H., Lönnqvist B., et al. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 5 (1990) 413-418
10. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., and Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102 (2003) 4255-4260
11. Ringdén O., Schaffer M., Le Blanc K., et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. Biol Blood Marrow Transplant 10 (2004) 128-134
12. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98 (2001) 2043-2051
13. Erard V., Guthrie K.A., Riddell S., and Boeckh M. Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation. Haematologica 91 (2006) 1377-1383
14. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 102 (2003) 1224-1231
15. Gustafsson Jernberg A., Remberger M., Ringdén O., and Winiarski J. Risk factors in pediatric stem cell transplantation for leukemia. Pediatr Transplant 8 (2004) 464-474
16. Bordon V., Bravo S., Van Renterghem L., et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transpl Infect Dis 10 (2008) 19-23
17. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
19. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
20. Cox D.R. Regression models and life-tables (with discussion). J R Stat Soc B34 (1972) 187-220
21. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1140-1154
22. Klein J.P. Modelling competing risks in cancer studies. Stat Med 25 (2006) 1015-1034
23. Klein J.P., and Andersen P.K. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics 61 (2005) 223-229
24. Klein J.P., Gerster M., Andersen P.K., Tarima S., and Perme M.P. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Programs Biomed 89 (2008) 289-300
25. Matthes-Martin S., Lion T., Aberle S.W., et al. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant 31 (2003) 803-808
26. Paulin T., Ringdén O., Lönnqvist B., Wahren B., and Nilsson B. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors. Scand J Infect Dis 18 (1986) 199-209
27. Meyers J.D., Fluornoy N., and Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153 (1986) 478-488
28. Mackall C.L., Fleisher T.A., Brown M.R., et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332 (1995) 143-149
29. Mackall C.L., Hakim F.T., and Gress R.E. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol 9 (1997) 339-346
30. Lilleri D., Fornara C., Chiesa A., Caldera D., Alessandrino E.P., and Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 93 (2008) 248-256